Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Gentian Diagnostics ASA ( (DE:6FK) ) is now available.
Gentian Diagnostics ASA has hit a setback in developing its NT proBNP assay, after internal investigations showed the current version does not perform robustly at low concentration ranges around key clinical cut-off levels. Management has decided to return the project to the optimisation phase and explore a redesign of the test, acknowledging higher development risk but aiming to determine whether a revised assay can still yield a viable, commercially relevant product.
As a result of the technical issues and required redesign work, the company cannot currently provide a reliable timeline for the Research Use Only release or the commercial launch of the NT proBNP assay and will present updated schedules in the second quarter of 2026. The delay, which also forces the postponement of a planned NT proBNP webcast, underscores execution risk in Gentian’s cardiac biomarker pipeline and may affect expectations around its heart failure diagnostics offering until clearer performance and timing data emerge.
More about Gentian Diagnostics ASA
Gentian Diagnostics ASA is a Norway-based developer and manufacturer of high-quality in vitro diagnostic reagents, with core expertise in immunoassays for infections, inflammation, kidney disease and heart failure. The company focuses on converting clinically relevant biomarkers to efficient, high-throughput analysers, serving global human and veterinary diagnostics markets from its Moss headquarters and offices in Sweden, the U.S. and China.
Average Trading Volume: 11,778
Current Market Cap: NOK891.4M
See more insights into 6FK stock on TipRanks’ Stock Analysis page.